PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications
Abstract Background Treatment of human lung squamous cell carcinoma (LUSC) using current targeted therapies is limited because of their diverse somatic mutations without any specific dominant driver mutations. These mutational diversities preventing the use of common targeted therapies or the combin...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-08-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12967-020-02473-y |
| _version_ | 1818189448660123648 |
|---|---|
| author | Hae-Yun Jung Tae Ho Kim Jong-Eun Lee Hong Kwan Kim Jong Ho Cho Yong Soo Choi Sumin Shin Se-Hoon Lee Hwanseok Rhee Hee Kyung Lee Hyun Jung Choi Hye Yoon Jang Seungjae Lee Jung Hee Kang Young Ae Choi Sanghyuk Lee Jinseon Lee Yoon La Choi Jhingook Kim |
| author_facet | Hae-Yun Jung Tae Ho Kim Jong-Eun Lee Hong Kwan Kim Jong Ho Cho Yong Soo Choi Sumin Shin Se-Hoon Lee Hwanseok Rhee Hee Kyung Lee Hyun Jung Choi Hye Yoon Jang Seungjae Lee Jung Hee Kang Young Ae Choi Sanghyuk Lee Jinseon Lee Yoon La Choi Jhingook Kim |
| author_sort | Hae-Yun Jung |
| collection | DOAJ |
| description | Abstract Background Treatment of human lung squamous cell carcinoma (LUSC) using current targeted therapies is limited because of their diverse somatic mutations without any specific dominant driver mutations. These mutational diversities preventing the use of common targeted therapies or the combination of available therapeutic modalities would require a preclinical animal model of this tumor to acquire improved clinical responses. Patient-derived xenograft (PDX) models have been recognized as a potentially useful preclinical model for personalized precision medicine. However, whether the use of LUSC PDX models would be appropriate enough for clinical application is still controversial. Methods In the process of developing PDX models from Korean patients with LUSC, the authors investigated the factors influencing the successful initial engraftment of tumors in NOD scid gamma mice and the retainability of the pathological and genomic characteristics of the parental patient tumors in PDX tumors. Conclusions The authors have developed 62 LUSC PDX models that retained the pathological and genomic features of parental patient tumors, which could be used in preclinical and co-clinical studies. Trial registration Tumor samples were obtained from 139 patients with LUSC between November 2014 and January 2019. All the patients provided signed informed consents. This study was approved by the institutional review board (IRB) of Samsung Medical Center (2018-03-110) |
| first_indexed | 2024-12-11T23:42:59Z |
| format | Article |
| id | doaj.art-9d93ac959c034382aa1b8870c7dc3a31 |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-11T23:42:59Z |
| publishDate | 2020-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-9d93ac959c034382aa1b8870c7dc3a312022-12-22T00:45:41ZengBMCJournal of Translational Medicine1479-58762020-08-0118111310.1186/s12967-020-02473-yPDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applicationsHae-Yun Jung0Tae Ho Kim1Jong-Eun Lee2Hong Kwan Kim3Jong Ho Cho4Yong Soo Choi5Sumin Shin6Se-Hoon Lee7Hwanseok Rhee8Hee Kyung Lee9Hyun Jung Choi10Hye Yoon Jang11Seungjae Lee12Jung Hee Kang13Young Ae Choi14Sanghyuk Lee15Jinseon Lee16Yoon La Choi17Jhingook Kim18Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDNA Link, IncDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDivision of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of MedicineDNA Link, IncDNA Link, IncDNA Link, IncDNA Link, IncDNA Link, IncDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineEwha Research Center for Systems Biology (ERCSB) and Department of Life Science, Ewha Womans UniversityDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of MedicineDepartment of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of MedicineAbstract Background Treatment of human lung squamous cell carcinoma (LUSC) using current targeted therapies is limited because of their diverse somatic mutations without any specific dominant driver mutations. These mutational diversities preventing the use of common targeted therapies or the combination of available therapeutic modalities would require a preclinical animal model of this tumor to acquire improved clinical responses. Patient-derived xenograft (PDX) models have been recognized as a potentially useful preclinical model for personalized precision medicine. However, whether the use of LUSC PDX models would be appropriate enough for clinical application is still controversial. Methods In the process of developing PDX models from Korean patients with LUSC, the authors investigated the factors influencing the successful initial engraftment of tumors in NOD scid gamma mice and the retainability of the pathological and genomic characteristics of the parental patient tumors in PDX tumors. Conclusions The authors have developed 62 LUSC PDX models that retained the pathological and genomic features of parental patient tumors, which could be used in preclinical and co-clinical studies. Trial registration Tumor samples were obtained from 139 patients with LUSC between November 2014 and January 2019. All the patients provided signed informed consents. This study was approved by the institutional review board (IRB) of Samsung Medical Center (2018-03-110)http://link.springer.com/article/10.1186/s12967-020-02473-yLung squamous cell carcinomaPatient-derived xenograftEngraftmentPreclinical modelXenograft-associated lymphoproliferative disease |
| spellingShingle | Hae-Yun Jung Tae Ho Kim Jong-Eun Lee Hong Kwan Kim Jong Ho Cho Yong Soo Choi Sumin Shin Se-Hoon Lee Hwanseok Rhee Hee Kyung Lee Hyun Jung Choi Hye Yoon Jang Seungjae Lee Jung Hee Kang Young Ae Choi Sanghyuk Lee Jinseon Lee Yoon La Choi Jhingook Kim PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications Journal of Translational Medicine Lung squamous cell carcinoma Patient-derived xenograft Engraftment Preclinical model Xenograft-associated lymphoproliferative disease |
| title | PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications |
| title_full | PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications |
| title_fullStr | PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications |
| title_full_unstemmed | PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications |
| title_short | PDX models of human lung squamous cell carcinoma: consideration of factors in preclinical and co-clinical applications |
| title_sort | pdx models of human lung squamous cell carcinoma consideration of factors in preclinical and co clinical applications |
| topic | Lung squamous cell carcinoma Patient-derived xenograft Engraftment Preclinical model Xenograft-associated lymphoproliferative disease |
| url | http://link.springer.com/article/10.1186/s12967-020-02473-y |
| work_keys_str_mv | AT haeyunjung pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT taehokim pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT jongeunlee pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT hongkwankim pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT jonghocho pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT yongsoochoi pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT suminshin pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT sehoonlee pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT hwanseokrhee pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT heekyunglee pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT hyunjungchoi pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT hyeyoonjang pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT seungjaelee pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT jungheekang pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT youngaechoi pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT sanghyuklee pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT jinseonlee pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT yoonlachoi pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications AT jhingookkim pdxmodelsofhumanlungsquamouscellcarcinomaconsiderationoffactorsinpreclinicalandcoclinicalapplications |